After “returning to local pharmaceutical enterprises” for a short time.
On April 20, Robert Davis, global president and CEO of MSD, announced that Joseph Romanelli would return to MSD in August, lead MSD Human Health International Department, join MSD Executive Committee and report directly to DFC, effective from August 1, 2022. Previously, Luo Wanli, President of MSD China, joined Jixing pharmaceutical on July 14, 2021. Jixing pharmaceutical is a privately held biopharmaceutical company headquartered in Shanghai. On the same day that MSD announced Rowan Li’s return, Jixing pharmaceutical announced the appointment of Dr. Peter Fong as the acting CEO. The new appointment will take effect from June 1, 2022.
In fact, many executives of local pharmaceutical companies, including Luo Wanli, who once ran away from multinational pharmaceutical companies, have recently announced their return. Mr. Qian, who has been the chief marketing officer of Pfizer and Mr. Luo Weimin for 80 months this year, has been the vice president of Pfizer for a short time.
The phenomenon of executives leaving multinational pharmaceutical companies flowing to local pharmaceutical companies once became a trend, and the “return” after short-term employment also changed this trend. What are the main drivers behind this? In this regard, at the Boao Forum for Asia 2022 annual meeting held recently, Wang Lei, global executive vice president and President of international business and China of AstraZeneca, told reporters of the 21st Century Business Herald that talent flow is normal. “The coming and going talent exchange is exactly what we want to see, and it is also a manifestation of the prosperity of China Meheco Group Co.Ltd(600056) industry.”
multinational pharmaceutical executives frequently “return”
In recent years, the number of executives of multinational pharmaceutical enterprises leaving their jobs to enter local enterprises has continued to increase, but many have returned to the role of multinational enterprises shortly after entering local pharmaceutical enterprises.
Qian Wei resigned at the end of June 2021 and then joined Shanghai Junshi Biosciences Co.Ltd(688180) as chief commercial officer, fully responsible for the company’s commercialization planning and business operation. After only four months of “short experience” of Chinese innovative pharmaceutical enterprises, Qian Wei returned to his old employer and was appointed general manager of Roche China customer interaction business model – tumor field, reporting directly to Bian Xin, President of Roche China. As everyone knows, Bian Xin, President of Roche China, joined Baiji Shenzhou, a local innovation leader, after 13 years in Xi’an Janssen, but returned to multinational pharmaceutical enterprises after only one year.
Following the return of Qian Wei, former chief commercial officer of Junshi, to Roche, Chu Nan, vice president of marketing and medical affairs of Junshi, also resigned and joined Pfizer on March 28. Chu Nan served as Marketing Director / Senior Marketing Director of Roche from 2016 to 2021, responsible for product portfolio strategy, launch of a series of new products and national marketing strategy in the field of breast and gastric cancer diseases. Subsequently, in Shanghai Junshi Biosciences Co.Ltd(688180) responsible for the tumor product portfolio strategy, the internationalization strategy of innovative drugs to the sea, China’s commercial market promotion, post market medical affairs and clinical operation.
This time, Chu Nan will join Pfizer as the person in charge of the field of digestive system / urinary / blood tumor treatment, responsible for managing the sales and marketing team in the field of digestive system / urinary / blood tumor treatment, formulating products and market strategies in relevant fields, developing and promoting the business development of product pipelines with strategic thinking, and helping to give full play to the potential of products to promote the rapid growth of business.
In addition to Pfizer and Roche, MSD also has frequent talent alternation. Previously, Li Zhengqing, global vice president and general manager of China R & D center of MSD, announced on March 1, 2019 that he would become chief medical officer and R & D president of Greater China of gelly pharmaceutical. After joining gelly, he returned to MSD just over four months later. Recently, MSD announced that Luo Wanli, the former president of China, who has left MSD for nine months, will return in August this year and serve as the president of the international market of MSD human health.
In addition, AstraZeneca China announced that it would officially establish the omni channel business unit from January 1, 2022, and appointed Liu Qian, vice president of AstraZeneca China, as the head of the omni channel business unit. Liu Qian is a well-known celebrity in the internet medical and pharmaceutical industry. He has more than 20 years of senior working experience in the pharmaceutical industry. He once chose to start his own business and returned to multinational pharmaceutical enterprises in 2018.
In view of the phenomenon that talents from local enterprises return to multinational pharmaceutical enterprises, Wang Lei believes that at present, it is normal to see some talents from foreign-funded enterprises acclimatized to local enterprises, and some return. It is a trend for people from Chinese start-ups to return to foreign-funded enterprises. This kind of exchange of talents is what we want to see and a manifestation of the prosperity of China Meheco Group Co.Ltd(600056) industry.
\u3000\u3000 “90% of AstraZeneca’s talents are trained internally, and our managers are internal, so we rarely recruit outside, and our opportunities are always left to internal colleagues. I think we will stick to this point. We can also attract good people in the industry to join, that is, the fresh blood in the school. But our management posts must be promoted internally. Once we encounter a bottleneck, he can develop outside, which is very important It is also AstraZeneca’s talent concept. Talent is unchanging and static, which is not what we want. ” Wang Lei said.
competition for talents between local pharmaceutical enterprises and multinational pharmaceutical enterprises
Behind the talent flow, local pharmaceutical enterprises and multinational pharmaceutical enterprises are constantly adjusting their strategies and talent structure to cope with the new trend of industry development. With the promotion of policies such as the normalization of centralized procurement and the negotiation of Medicare catalogue drugs, multinational pharmaceutical enterprises are forced to reduce costs by stripping off “non core business” and adjusting talent structure, respond to market changes and seek new growth points.
According to the data of Zhongkang technology, due to the implementation of centralized procurement, the growth rate of multinational enterprises in 2021 is less than that of local enterprises. In terms of the nature of different enterprises, local enterprises dominate the hospital drug market, with sales of nearly 680.5 billion yuan in 2021, an increase of 12% year-on-year, but looking at the trend of sales proportion in the five years, it shows a downward trend. The proportion of multinational enterprises has gradually expanded, reaching 307.7 billion yuan in 2021, with a growth rate of 5%. Although the growth rate is not as good as that of local enterprises, the victory is steady.
At the same time, local pharmaceutical companies have launched innovative pharmaceutical products one after another, and the demand for talents is becoming more and more urgent under the huge market potential. Iqvia predicts that local pharmaceutical enterprises will have two development directions in the future: first, first in class enterprises participating in global competition. Its international positioning is far-sighted, and it will still move forward tortuously in the short term. Such enterprises will lead the international development and innovation breakthrough of China’s biomedicine. Second, China’s leading high-quality me better enterprises. Such enterprises are based on the Chinese market, win by scale in the short term, and gradually transform to innovation in the medium and long term. They will be major contributors to China Meheco Group Co.Ltd(600056) industrial upgrading.
Therefore, for local pharmaceutical enterprises that urgently need to build R & D pipelines, there is an urgent need for talents with rich experience to join in order to control the listing of innovative pharmaceutical products.
In this context, the choice of executives of multinational pharmaceutical enterprises to leave may be determined by comprehensive consideration of the impact brought by centralized procurement, enterprise performance, industry prospect, exhibition space and other factors. However, behind the personnel phenomenon of returning after leaving, there are also reasons for personal choice.
Industry insiders believe that domestic and foreign enterprises have great differences in cultural atmosphere and functional scope. The established multinational pharmaceutical enterprises not only have a deep brand culture, but also have a more sound division of labor system, and pay more attention to the cooperation within the team. After joining the domestic funded enterprises, the executives who are used to the management mode of foreign-funded enterprises need to quickly adjust their mentality from all aspects to better integrate into the new working system and corporate culture, which also makes the foreign executives may have values, culture Capital and other “acclimatized” situations, so the decision to leave was made. Therefore, for local innovative drug enterprises, how to retain talents after introducing talents is also a crucial issue.
At present, with the continuous development and changes of the industry, the flow of senior executives of pharmaceutical enterprises will also tend to be frequent. According to the analysis of Zhongkang technology, with China’s medical reform entering the deep-water area, especially under the pressure of a series of reforms such as volume procurement, medical insurance negotiation and DRGs, generic drugs are rapidly declining and innovative drugs are gradually rising, and the whole industry is facing the urgent need of transformation and upgrading. This also means that the China Meheco Group Co.Ltd(600056) industry will continue to develop and change rapidly in the next few years, including personnel changes, mergers and acquisitions, etc. Among them, the turnover of core executives of pharmaceutical innovation enterprises will become more frequent, and the competition for high-level talents will become more and more intense.
This also makes that in today’s increasingly fierce competition for talents, domestic pharmaceutical enterprises need to more actively absorb high-end talents. Only by further retaining talents can they really achieve better development with the help of the value of talents. As for multinational pharmaceutical enterprises, as Wang Lei said: Talents in multinational pharmaceutical enterprises including AstraZeneca will encounter a temporary bottleneck, and it is impossible for everyone to rise all the way to the end. In particular, executives need to leave to become bigger executives to help the whole China Meheco Group Co.Ltd(600056) industry export talents. This is also one of the important missions of multinational pharmaceutical enterprises.
